Lianke Liu
Overview
Explore the profile of Lianke Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
469
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang M, Sun J, Hu C, Wu L, Fan Y, Wang Z, et al.
Med
. 2024 Oct;
6(2):100516.
PMID: 39395411
Background: Anti-PD-1 immunotherapy plus chemotherapy (combo) exhibits significantly prolonged survival for squamous cell lung cancer (LUSC). An exploration of predictive biomarkers is still needed. Methods: High-throughput RNA sequencing (RNA-seq) of...
2.
Cheng Y, Pan Z, Wu L, Zhu B, Yu Y, Zang K, et al.
Adv Ther
. 2024 Sep;
41(11):4032-4048.
PMID: 39230871
Introduction: SCT510 is a biosimilar to bevacizumab (Avastin) reference product (RP) that is approved for various metastatic cancers. In this study, we aimed to demonstrate the equivalence of SCT510 and...
3.
Lu Z, Kong L, Wang B, Wang J, Liu L, Shu Y, et al.
EClinicalMedicine
. 2024 May;
72:102623.
PMID: 38800802
Background: In ORIENT-15 study, sintilimab plus chemotherapy demonstrated significant improvement on overall survival (OS) versus placebo plus chemotherapy in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC). Here, we...
4.
Li J, Chen Z, Bai Y, Liu B, Li Q, Zhang J, et al.
Nat Med
. 2024 Feb;
30(3):740-748.
PMID: 38302715
Although antiprogrammed death 1 antibody plus chemotherapy has recently been approved for first-line esophageal squamous cell carcinoma (ESCC), antiprogrammed death-ligand 1 antibody may offer another combination option in this setting....
5.
Zhao S, Ma Y, Liu L, Fang J, Ma H, Feng G, et al.
Lung Cancer
. 2024 Jan;
188:107468.
PMID: 38181454
Background: MET and AXL dysregulations are implicated in acquired resistance to EGFR-TKIs in NSCLC. But consensus on the optimal definition for MET/AXL dysregulations in EGFR-mutant NSCLC is lacking. Here, we...
6.
Wang R, Shi M, Ji M, Han Z, Chen L, Liu Y, et al.
Transl Lung Cancer Res
. 2023 May;
12(4):786-796.
PMID: 37197631
Background: Camrelizumab has shown promising survival benefits in treatment-naïve advanced non-small cell lung cancer (NSCLC) patients when used in combination with chemotherapy. However, its effectiveness and safety outside the clinical...
7.
8.
Wang T, Shao Q, Xiao C, Liu L
Front Oncol
. 2023 Mar;
13:1124730.
PMID: 36998454
Immunotherapy has become a very effective treatment for many cancers. It has a unique set of immune system-related adverse effects, collectively known as immune-related adverse events (irAEs). Skin toxicities are...
9.
Xu F, Xiao C, Sun W, He Y, Chalela R, Masuda K, et al.
Ann Transl Med
. 2022 Sep;
10(16):912.
PMID: 36111030
Background: Lung cancer is a malignant tumor with high morbidity and mortality worldwide. At present, the main treatment methods for patients with advanced non-small cell lung cancer (NSCLC) include molecular...
10.
Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, et al.
BMJ
. 2022 Apr;
377:e068714.
PMID: 35440464
Objective: To evaluate sintilimab versus placebo in combination with chemotherapy (cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil) as first line treatment of unresectable locally advanced, recurrent, or metastatic oesophageal squamous...